B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2602-2610

  Cozma, Diana ^a   Yu, Duonan ^a   Hodawadekar, Suchita ^a   Azvolinsky, Anna ^a   Grande, Shannon ^a   Tobias, John W ^a   Metzgar, Michele H ^b   Paterson, Jennifer ^c   Erikson, Jan ^b   Marafioti, Teresa ^c   Monroe, John G ^a   Atchison, Michael L ^a   Thomas Tikhonenko, Andrei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BREAKPOINT CLUSTER REGION PROTEIN; CD22 ANTIGEN; CD79A ANTIGEN; HYBRID PROTEIN; MESSENGER RNA; PROTEIN KINASE SYK; TAMOXIFEN; TRANSCRIPTION FACTOR PAX5; TYROSINE;

ANIMAL CELL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; CANCER GROWTH; CARCINOGENESIS; CELL STIMULATION; CONTROLLED STUDY; DNA FINGERPRINTING; GENE SILENCING; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 34848896885     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30842     Document Type: Article

References (59)

1. Taub, R., et al. 1982. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. U. S. A. 79:7837-7841.
2. Dalla-Favera, R., et al. 1982. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U. S. A. 79:7824-7827.
3. Shen-Ong, G.L., Keath, E.J., Piccoli, S.P., and Cole, M.D. 1982. Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. Cell. 31:443-452.
4. Adams, J.M., et al. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 318:533-538.
5. Schmidt, E.V., Pattengale, P.K., Weir, L., and Leder, P. 1988. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model. Proc. Natl. Acad. Sci. U. S. A. 85:6047-6051.
6. Kovalchuk, A.L., et al. 2000. Burkitt lymphoma in the mouse. J. Exp. Med. 192:1183-1190.
7. Park, S.S., et al. 2005. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 65:1306-1315.
8. Yu, D., and Thomas-Tikhonenko, A. 2002. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene. 21:1922-1927.
9. Hagman, J., and Lukin, K. 2006. Transcription factors drive B cell development. Curr. Opin. Immunol. 18:127-134.
10. Barr, F.G. 1997. Chromosomal translocations involving paired box transcription factors in human cancer. Int. J. Biochem. Cell Biol. 29:1449-1461.
11. Urbanek, P., Wang, Z.Q., Fetka, I., Wagner, E.F., and Busslinger, M. 1994. Complete block of early B-cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell. 79:901-912.
12. Mikkola, I., Heavey, B., Horcher, M., and Busslinger, M. 2002. Reversion of B cell commitment upon loss of Pax5 expression. Science. 297:110-113.
13. Husson, H., et al. 2002. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 99:282-289.
14. Pasqualucci, L., et al. 2001. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 412:341-346.
15. Montesinos-Rongen, M., Van Roost, D., Schaller, C., Wiestler, O.D., and Deckert, M. 2004. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood. 103:1869-1875.
16. Gaidano, G., et al. 2003. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood. 102:1833-1841.
17. Krenacs, L., et al. 1998. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood. 92:1308-1316.
18. Cook, J.R., et al. 2004. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum. Pathol. 35:447-454.
19. Offit, K., Parsa, N.Z., Filippa, D., Jhanwar, S.C., and Chaganti, R.S. 1992. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood. 80:2594-2599.
20. Iida, S., et al. 1996. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood. 88:4110-4117.
21. Busslinger, M., Klix, N., Pfeffer, P., Graninger, P.G., and Kozmik, Z. 1996. Deregulation of PAX-5 by translocation of the E? enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 93:6129-6134.
22. Morrison, A.M., et al. 1998. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood. 92:3865-3878.
23. Cazzaniga, G., et al. 2001. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res. 61:4666-4670.
24. Stuart, E.T., Kioussi, C., Aguzzi, A., and Gruss, P. 1995. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin. Cancer Res. 1:207-214.
25. Baumann Kubetzko, F.B., et al. 2004. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis. 25:1839-1846.
26. Souabni, A., Jochum, W., and Busslinger, M. 2006. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus. Blood. 109:281-289.
27. Bousquet, M., et al. 2007. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 109:3417-3423.
28. Mullighan, C.G., et al. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 446:758-764.
29. Tierney, R., Kirby, H., Nagra, J., Rickinson, A., and Bell, A. 2000. The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J. Virol. 74:10458-10467.
30. Stuart, E.T., Haffner, R., Oren, M., and Gruss, P. 1995. Loss of p53 function through Pax-mediated transcriptional repression. EMBO J. 14:5638-5645.
31. Yu, D., et al. 2003. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood. 101:1950-1955.
32. Johnson, K., et al. 2004. B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. Nat. Immunol. 5:853-861.
33. Hodawadekar, S., et al. 2006. B-lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages. Exp. Cell Res. 313:331-340.
34. Hodawadekar, S., Wei, F., Yu, D., Thomas-Tikhonenko, A., and Atchison, M. 2006. Epigenetic histone modifications do not control Igk locus contraction and intranuclear localization in cells with dual B cell-macrophage potential. J. Immunol. 177:6165-6171.
35. Monroe, J.G. 2006. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat. Rev. Immunol. 6:283-294.
36. Chiang, M.Y., and Monroe, J.G. 2001. Role for transcription Pax5A factor in maintaining commitment to the B cell lineage by selective inhibition of granulocyte-macrophage colony-stimulating factor receptor expression. J. Immunol. 166:6091-6098.
37. Maitra, S., and Atchison, M. 2000. BSAP can repress enhancer activity by targeting PU.1 function. Mol. Cell. Biol. 20:1911-1922.
38. Kanehisa, M. 1997. A database for post-genome analysis. Trends Genet. 13:375-376.
39. Dennis, G., Jr., et al. 2003. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4:P3.
40. Schebesta, M., Pfeffer, P.L., and Busslinger, M. 2002. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity. 17:473-485.
41. Fitzsimmons, D., et al. 1996. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev. 10:2198-2211.
42. Kozmik, Z., Wang, S., Dorfler, P., Adams, B., and Busslinger, M. 1992. The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP. Mol. Cell. Biol. 12:2662-2672.
43. Bannish, G., Fuentes-Panana, E.M., Cambier, J.C., Pear, W.S., and Monroe, J.G. 2001. Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J. Exp. Med. 194:1583-1596.
44. Grande, S.M., et al. 2006. Cellular ITAM-containing proteins are oncoproteins in nonhematopoietic cells. Oncogene. 25:2748-2757.
45. Nitschke, L. 2005. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr. Opin. Immunol. 17:290-297.
46. Gururajan, M., Jennings, C.D., and Bondada, S. 2006. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J. Immunol. 176:5715-5719.
47. Delogu, A., et al. 2006. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity. 24:269-281.
48. Nera, K.P., et al. 2006. Loss of Pax5 promotes plasma cell differentiation. Immunity. 24:283-293.
49. Reth, M., and Wienands, J. 1997. Initiation and processing of signals from the B cell antigen receptor. Annu. Rev. Immunol. 15:453-479.
50. Allman, D., Srivastava, B., and Lindsley, R.C. 2004. Alternative routes to maturity: branch points and pathways for generating follicular and marginal zone B cells. Immunol. Rev. 197:147-160.
51. Smith, S.H., and Reth, M. 2004. Perspectives on the nature of BCR-mediated survival signals. Mol. Cell. 14:696-697.
52. Torres, R.M., Flaswinkel, H., Reth, M., and Rajewsky, K. 1996. Aberrant B cell development and immune response in mice with a compromised BCR complex. Science. 272:1804-1808.
53. Lam, K.P., Kuhn, R., and Rajewsky, K. 1997. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 90:1073-1083.
54. Kraus, M., Alimzhanov, M.B., Rajewsky, N., and Rajewsky, K. 2004. Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell. 117:787-800.
55. Petlickovski, A., et al. 2005. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 105:4820-4827.
56. Irish, J.M., Czerwinski, D.K., Nolan, G.P., and Levy, R. 2006. Altered B cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor infiltrating non-malignant B cells. Blood. 108:3135-3142.
57. Kuppers, R. 2005. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer. 5:251-262.
58. Gururajan, M., et al. 2005. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood. 106:1382-1391.
59. Maraf ioti, T., et al. 2004. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood. 103:188-193.